Indian Journal of Urology Users online:1750  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size
RESEARCH ARTICLE
Year : 2003  |  Volume : 20  |  Issue : 1  |  Page : 54-58

Monotherapy with docetaxel in treatment of hormone resistant cancer of the prostate - our results


Department of Urology, VM Medical College and Safdarjang Hospital, New Delhi, India

Correspondence Address:
N K Mohanty
C-II/124, Moti Bagh-1, New Delhi - 110 021
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objectives: Management of hormone resistant prostate cancer (HRCaP) is always a challenge to urologist. Mi­crotubule inhibitors have been in focus as chemothera­peutic agents in carcinoma prostate, docetaxel being the most active among such drugs. The present study aims to evaluate the efficacy and safety of docetaxel as a single agent in the management of HRCaP. Methods: Twenty patients of HRCaP between 58-82 years of age were enrolled to receive docetaxel 75mg/sq.m. intravenously every 3'd week with a minimum 6 dose sched­ule. A total number of 136 doses were used. All patients were D3 stage disease and symptomatic. Median prostate specific antigen (PSA) at the time of entry was 180ng/ml and the median follow up was for 28 months. Results: An objective response in PSA reduction by = 80% was observed in 5 patients (25%) and more than 25% reduction seen in 12 patients (60%). Seventy percent of the patients showed improvement in symptoms on treat­ment. In 12 patients (60%), the disease was stable and showed response for a median period of 18 months. The median overall survival was 22 months. Adverse reaction in the form of anaemia, neutropenia, leucopenia was seen in 20 patients (100%), stomatitis, fever and alopecia was seen in 12 patients (60%). Four developed oral thrush (20%). Mortality occurred in 5 patients (25%) during the study, 2 died from pulmonary metastasis and 3 had cer­ebral metastasis with paraplegia. Conclusions: The response seen in this study is very encouraging and suggests substantial durable activity of docetaxel as a single therapy in HRCaP


[FULL TEXT] [PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2406    
    Printed88    
    Emailed1    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

 

HEALTHWARE INDIA